Skip to content

Intra-Hospital Transport of Critically Ill Patients in Intensive Care Unit

Intra-Hospital Transport of Critically Ill Patients in Intensive Care Unit

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06455696
Acronym
TIGRHOU
Enrollment
645
Registered
2024-06-12
Start date
2024-01-01
Completion date
2025-06-30
Last updated
2024-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Intensive Care Unit, Transportation Accidents

Keywords

Intra-hospital transport, Critical ill patients, Intensive care unit

Brief summary

Intra-hospital transport is a frequent procedure in the ICU, involving patients with the highest severity scores. Although some studies estimate the rate of adverse events to be around 33% during intra-hospital transport, including 4% of serious adverse events, the epidemiological data available is small, heterogeneous, and probably subject to methodological bias. The aim of this study observational prospective observatoinal study is to determine: * the different practices existing between ICUs (practice survey) * the occurrence of adverse events during intra-hospital transport provided by intensive care units (epidemiological study)

Detailed description

This is a multicenter prospective observational study on evaluation of practices between ICUs and to describe the occurence of adverse events during intra-hospital transport provided by ICUs (epidemiological study)

Interventions

None listed

Sponsors

French Society for Intensive Care
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged over 18 years old * Hospitalized in ICU * Requiring an intra-hospital transport (e.g imagery, operating room, etc) by the ICU team * With a departure from ICU and arrival to ICU

Exclusion criteria

* Person under guardianship * Protected Majors * Already included in the study * Transport for an ICU discharge in a medical or surgical ward * Transport with another team than the ICU team * Not affiliated to French social security

Design outcomes

Primary

MeasureTime frameDescription
Incidence of adverse events during intra-hospital transport in critical ill patients managed by an ICU teamDuring the intra-intrahospital transport [maximum 3 hours]The number of adverse events during intra-hospital transport managed by an ICU team, as a proportion of the number of transports performed.

Secondary

MeasureTime frameDescription
Incidence of non-serious adverse events occurring during intra-hospital transport.During the intra-intrahospital transport [maximum 3 hours]3\) Rate of types of (non-serious) adverse events occurring during intra-hospital transport including O Rate of Withdrawal or mobilization of equipment with low risk of serious complication (e.g. VVP withdrawal, urinary catheter, nasogastric tube, mobilization of endotracheal tube without extubation) O Rate of Non-severe hemodynamic failures (occurrence of arterial hypotension with MAP between 40 and 65 mmHg, or catecholamine increase \< 10% during transport) O Rate of Non-severe respiratory failure (desaturation with a SpO2 ≥ 80%) O Rate of Metabolic failure (e.g. hypoglycemia on return from transport) O Rate of Neurological complications (consciousness disorders occurring without sedation, agitation) O Rate of Material failures (O2 or ventilator failure, electrical syringe pump failure)
Incidence of serious adverse events occurring during intra-hospital transport.During the intra-intrahospital transport [maximum 3 hours]4\) Rate of serious adverse events occurring during intra-hospital transport including O Death O Cardiorespiratory arrest O Accidental extubation and/or need for re-intubation, or removal of high-risk equipment (e.g. central venous catheter, arterial catheter, endotracheal tube) O Severe hemodynamic failure (arterial hypotension with MAP \< 40 mmHg, introduction or increase of catecholamines ≥ 10% during transport) O Severe respiratory failure (desaturation with SpO2 \< 80% or massive inhalation)

Countries

France

Contacts

Primary ContactRaphaël CLERE-JEHL
raphael.clere@gmail.com+33 1 45 86 51 99

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026